Thursday, May 29, 2025 5/29/2025

A Period Seroprevalence (SARS-CoV-2) Survey in MHCCN Cancer Healthcare Workers (HCWs) Providing Patient Care during the Height of the Outbreak: A Registry Study

Award Number: UG1CA239771
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Description

A Period Seroprevalence (SARS-CoV-2) Survey in MHCCN Cancer Healthcare Workers (HCWs) Providing Patient Care during the Height of the Outbreak: A Registry Study - In December 2019, the emergence of an as yet uncharacterized pneumonia in Wuhan, China heralded the onset of the coronavirus pandemic caused by Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2). The etiology and disease profile, aka Coronavirus Disease-2019 (COVID-19), has been quickly elucidated; though there is considerable lack of understanding of viral transmission. Public health measures to mitigate and contain the outbreak are hampered by scarcity and scaling up testing. The virus is among the most contagious in our lifetimes and thought to be primarily transmitted by droplet infection. Viral transmission also occurs by airborne routes and during asymptomatic periods of infection, which complicates public health measures. This is further compounded by lack of Personal Protective Equipment (PPE) and different strategies for use. These realities place Healthcare Workers (HCWs) at risk providing care to known infected patients and Persons Under Investigation (PUIs) with high suspicion of COVID-19. We propose a hypothesis-driven period sero-prevalence study of SARS-CoV-2 in MaineHealth Cancer Care Network (MHCCN) cancer Healthcare Workers (HCWs) at a sizeable rural health system and academic medical center. Our study is predicated on the lack of sound sero-epidemiological data to define occupational exposure and risk of SARS-CoV-2 infection in our cancer providers. We anticipate brisk recruitment of our cancer HCWs (Aim 1) and roll-out of a sero-antibody (IgG/IgM) test (Aim 2) to determine exposure. Brief clinical and occupational surveys will be completed. This cohort is invaluable to sustain and provide information on the SARS-CoV-2-transmission dynamics that will guide continued response to this pandemic, especially with an anticipated second wave that will inform cancer care in the rural community setting. This project is submitted in response to NOT-CA-20-0421 and is closely integrated and tethered to MaineHealth Lifespan NCORP (1UG1 CA239771-01) the parent grant that was submitted and subsequently awarded under PA-18-591.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = -$54,064 )
2025	2024	MAINEHEALTH	110 FREE ST	PORTLAND	ME	04101	CUMBERLAND	USA	Cancer Control	000	6	12/9/2024	NON-COMPETING CONTINUATION	$0
2025	2020	MAINEHEALTH	110 FREE ST	PORTLAND	ME	04101	CUMBERLAND	USA	Cancer Detection and Diagnosis Research	001	2	4/8/2025	SUPPLEMENT FOR EXPANSION	-$54,064
														Subtotal = -$54,064

Issue Date FY: 2024 ( Subtotal = $1,076,001 )
2024	2024	MAINEHEALTH	110 FREE ST	PORTLAND	ME	04101	CUMBERLAND	USA	Cancer Control	001	6	7/29/2024	NON-COMPETING CONTINUATION	$1,076,001
2024	2023	MAINEHEALTH	110 FREE ST	PORTLAND	ME	04101	CUMBERLAND	USA	Cancer Control	000	5	2/15/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $1,076,001

Issue Date FY: 2023 ( Subtotal = $1,109,279 )
2023	2023	MAINEHEALTH	22 BRAMHALL ST	PORTLAND	ME	04102	CUMBERLAND	USA	Cancer Control	001	5	7/28/2023	NON-COMPETING CONTINUATION	$1,109,279
2023	2022	MAINEHEALTH	22 BRAMHALL ST	PORTLAND	ME	04102	CUMBERLAND	USA	Cancer Control	000	4	4/4/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $1,109,279

Issue Date FY: 2022 ( Subtotal = $1,050,305 )
2022	2022	MAINEHEALTH	22 BRAMHALL ST	PORTLAND	ME	04102	CUMBERLAND	USA	Cancer Control	003	4	8/1/2022	NON-COMPETING CONTINUATION	$1,050,305
2022	2021	MAINEHEALTH	22 BRAMHALL ST	PORTLAND	ME	04102	CUMBERLAND	USA	Cancer Control	002	3	5/26/2022	NON-COMPETING CONTINUATION	$0
2022	2021	MAINEHEALTH	22 BRAMHALL ST	PORTLAND	ME	04102	CUMBERLAND	USA	Cancer Control	000	3	4/11/2022	NON-COMPETING CONTINUATION	$0
2022	2020	MAINEHEALTH	22 BRAMHALL ST	PORTLAND	ME	04102	CUMBERLAND	USA	Cancer Control	001	2	5/25/2022	NON-COMPETING CONTINUATION	$0
2022	2020	MAINEHEALTH	22 BRAMHALL ST	PORTLAND	ME	04102	CUMBERLAND	USA	Cancer Detection and Diagnosis Research	004	2	8/5/2022	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $1,050,305

Issue Date FY: 2021 ( Subtotal = $837,517 )
2021	2021	MAINEHEALTH	22 BRAMHALL ST	PORTLAND	ME	04102	CUMBERLAND	USA	Cancer Control	003	3	7/20/2021	NON-COMPETING CONTINUATION	$837,517
2021	2020	MAINEHEALTH	22 BRAMHALL ST	PORTLAND	ME	04102	CUMBERLAND	USA	Cancer Detection and Diagnosis Research	004	2	7/30/2021	SUPPLEMENT FOR EXPANSION	$0
2021	2020	MAINEHEALTH	22 BRAMHALL ST	PORTLAND	ME	04102	CUMBERLAND	USA	Cancer Detection and Diagnosis Research	001	2	10/20/2020	SUPPLEMENT FOR EXPANSION	$0
2021	2020	MAINEHEALTH	22 BRAMHALL ST	PORTLAND	ME	04102	CUMBERLAND	USA	Cancer Control	002	2	3/1/2021	NON-COMPETING CONTINUATION	$0
2021	2020	MAINEHEALTH	22 BRAMHALL ST	PORTLAND	ME	04102	CUMBERLAND	USA	Cancer Control	000	2	10/20/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $837,517

Issue Date FY: 2020 ( Subtotal = $966,436 )
2020	2020	MAINEHEALTH	22 BRAMHALL ST	PORTLAND	ME	04102	CUMBERLAND	USA	Cancer Control	000	2	7/27/2020	NON-COMPETING CONTINUATION	$837,517
2020	2020	MAINEHEALTH	22 BRAMHALL ST	PORTLAND	ME	04102	CUMBERLAND	USA	Cancer Detection and Diagnosis Research	002	2	9/17/2020	SUPPLEMENT FOR EXPANSION	$0
2020	2020	MAINEHEALTH	22 BRAMHALL ST	PORTLAND	ME	04102	CUMBERLAND	USA	Cancer Detection and Diagnosis Research	001	2	9/15/2020	SUPPLEMENT FOR EXPANSION	$128,919
														Subtotal = $966,436

Issue Date FY: 2019 ( Subtotal = $855,938 )
2019	2019	MAINEHEALTH	22 BRAMHALL ST	PORTLAND	ME	04102	CUMBERLAND	USA	Cancer Control	001	1	8/16/2019	NEW	$0
2019	2019	MAINEHEALTH	22 BRAMHALL ST	PORTLAND	ME	04102	CUMBERLAND	USA	Cancer Control	000	1	8/13/2019	NEW	$855,938
														Subtotal = $855,938

Grand Total All Awards = $5,841,412

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A Period Seroprevalence (SARS-CoV-2) Survey in MHCCN Cancer Healthcare Workers (HCWs) Providing Patient Care during the Height of the Outbreak: A Registry Study

Award Number: UG1CA239771

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer